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1 Introduction {#sec005}
==============

The mortality rate in patients with hemodynamic instability due to pelvic bone fractures remains high despite the development of several hemostatic modalities \[[@pone.0236645.ref001]--[@pone.0236645.ref005]\]. Recent studies have shown that preperitoneal pelvic packing (PPP) can be an effective hemostatic method for damage control surgery \[[@pone.0236645.ref006]--[@pone.0236645.ref008]\].

Among commercially available hemostatic gauzes, QuikClot Combat Gauze (QCG; Z-Medica, Wallingford, CT, USA), a hydrophilic gauze impregnated with kaolin, enhances hemostasis by activating the intrinsic pathway. It was first used in trauma cases with hemorrhaging external wounds but has recently been used for patients with intracorporeal hemorrhage \[[@pone.0236645.ref009], [@pone.0236645.ref010]\].

A study using a hypothermic coagulopathic swine model showed that, compared to plain gauze, kaolin-impregnated gauze for packing in cases of high-grade liver injuries reduced postoperative hemorrhage \[[@pone.0236645.ref011]\].

The present study aimed to evaluate the effectiveness of kaolin-impregnated hemostatic gauze in PPP for patients with hemodynamic instability due to severe pelvic fractures.

2 Material and methods {#sec006}
======================

2.1 Patient selection and data collection {#sec007}
-----------------------------------------

This retrospective study was approved by the institutional review board of a tertiary university hospital (IRB no. CR319078). Medical data of patients with pelvic fractures were collected from the hemodynamically unstable pelvic bone fracture registry of this tertiary university hospital, which is part of the Korean Trauma Data Bank. Data were collected prospectively and analyzed retrospectively. Because the data were analyzed anonymously, informed consent was waived. The inclusion criteria were: 1) hemodynamically unstable pelvic fracture, and 2) age \> 19 years. Seventy-five patients with hemodynamic instability due to pelvic fractures who were admitted to the regional trauma center of the tertiary university hospital between May 2014 and October 2018 were enrolled in the study. After the exclusion of 22 patients who did not receive PPP, 53 patients were included. These patients were divided into a hemostatic gauze group (HG group, n = 22) and a control group (n = 31) ([Fig 1](#pone.0236645.g001){ref-type="fig"}). Hemostatic gauze was commonly used as a standard of care in our hospital. When performing PPP, there were no criteria for the use of hemostatic gauze and its use was determined by the surgeon.

![Study flow chart.\
PPP, preperitoneal pelvic packing.](pone.0236645.g001){#pone.0236645.g001}

2.2 Patient management {#sec008}
----------------------

Hemodynamic instability was defined as persistent hypotension (systolic blood pressure \< 90 mmHg), even after 2 L of crystalloid loading or transfusion of 2 units of packed red blood cells (RBCs). When patients were admitted to the trauma bay with pelvic bone fractures and hemodynamic instability, they underwent extended focused assessment with sonography for trauma and a trauma series of X-rays (lateral cervical spine, chest anteroposterior \[AP\], and pelvis AP). Thoracoabdominal injuries were evaluated using the images. Based on the results, emergency thoracotomy or laparotomy was performed. After pelvic binders were applied to reduce pelvic volume, PPP was performed for patients with pelvic ring injuries based on pelvic AP imaging results. Orthopedic surgeons on the trauma team then determined whether external fixation of the pelvic fractures should be performed. The management protocol for hemodynamically unstable pelvic fractures was initiated in our trauma center in May 2014 according to management protocols created by the Rocky Mountain Regional Trauma Center at Denver Health \[[@pone.0236645.ref012]\].

Following the protocol, secondary pelvic angiography following PPP was performed in cases of ongoing bleeding even if PPP was performed. Embolization procedures were performed in cases of contrast media extravasations during pelvic angiography. In all pelvic fracture patients with shock, pelvic binders were applied in the Emergency Room (ER) and then were removed after patients became hemodynamically stable. In cases requiring external fixator (EF) application, pelvic binders were not re-applied; rather, these were re-applied just after PPP, but only in cases without EF use. In our institution, C-clamp was not used and supra-acetabular EF was performed for all pelvic external fixations. Prophylactic antibiotics were administered preoperatively to patients who underwent PPP and were continued until the second look.

2.3 PPP techniques and use of hemostatic gauze {#sec009}
----------------------------------------------

PPP was performed by trauma surgeons who successfully completed Definitive Surgical Trauma Care (DSTC^TM^) training provided by the International Association for Trauma Surgery and Intensive Care. After creating a 7--8 cm vertical skin incision beginning at the pubis symphysis, the anterior sheath of the rectus abdominis muscle was resected and the muscle was split. After the preperitoneal space was bluntly dissected in the posterolateral direction and the peritoneum migrated to the medial side, the lower border of the sacroiliac (SI) joint was examined. Three surgical pads were sequentially packed from the lower border of the SI joint using ringed forceps. This procedure was repeated on the contralateral side. After coagulopathy, hypothermia, and metabolic acidosis were corrected, packed surgical pads were removed and the abdominal wall was repaired within 48 hours \[[@pone.0236645.ref013]\]. One kaolin-impregnated gauze (QCG) and two surgical pads were used for patients in the HG group. After one QCG was packed into the lower border of the SI joint, two surgical pads were also packed. This procedure was repeated on the contralateral side. Patients in the control group were treated with the same procedure; however, the packing consisted of three plain surgical pads and no QCG.

2.4 Kaolin-impregnated hemostatic gauze {#sec010}
---------------------------------------

QCG is currently the Committee on Tactical Combat Casualty Care-recommended standard hemostatic agent of the United States military. It is a nonwoven surgical gauze coated in kaolin (aluminosilicate clay) that activates the intrinsic coagulation pathway. QCG has equal or higher efficacy in laboratory tests than other hemostatic agents including TraumaStat (Ore-Medix, Salem, OR, USA), Celox-D (SAM Medical, Portland, OR, USA), and HemCon RTS bandage (HemCon, Portland, OR, USA). QCG appeared to produce no short-term vascular damage compared with standard gauze in an animal model, and no adverse reactions during its use on the battlefield during Operation Cast Lead in the Gaza Strip \[[@pone.0236645.ref014]\].

2.5 Outcome evaluations {#sec011}
-----------------------

The primary study outcome was the rate of hemorrhage-induced mortality. The secondary outcomes were requirement of packed RBCs (during the initial 4 hours and after an additional 12 hours), length of intensive care unit (ICU) stay, and length of hospital stay.

2.6 Statistical analysis {#sec012}
------------------------

Continuous variables are presented as mean ± standard deviation or median (range). The chi-square test, Student's t-test, Fisher's exact test, and Mann-Whitney U test were used to compare the groups. For propensity score matching (PSM), logistic regression analysis was performed for all baseline features that differed between the HG group and control group on multivariate analysis. A propensity score for the predicted probability of a patient using hemostatic gauze was estimated using a multivariable logistic regression model. The C-statistic of the logistic regression model for PSM was 0.703. Adjusted covariates in PSM included age (\>75 years), sex, and highest lactate level (\>4 mmol/L). Using the nearest neighbor matching method, the absolute values of the differences in the estimated propensity scores of all patients in the HG group and control group were paired from smallest to largest. P values \< 0.05 were considered statistically significant. All calculations were performed using SAS 9.4 (SAS Institute, Cary, NC, USA).

3 Results {#sec013}
=========

3.1 Clinical characteristics of patients with hemodynamic instability due to pelvic fractures {#sec014}
---------------------------------------------------------------------------------------------

The mean patient age was 60.7 ± 17.9 years; 32 patients (60.4%) were male. The mean injury severity score was 40.2 ± 11.0 and the highest serum lactate level at the time of arrival at the ER was 6.74 ± 4.13 mmol/L. According to the Young-Burgess classification of pelvic fracture types, 13 patients (24.5%) had lateral compression fracture type III, 17 (32.1%) had lateral compression fracture type II, and 16 (30.2%) had vertical shearing. Four patients (7.5%) had anteroposterior compression (APC) type III, while 2 patients (3.8%) had APC type II. Pelvic angioembolizations were performed in 12 patients (22.6%). Hemostatic gauze was used for 21 patients (39.6%). A total of 21.8 ± 11.6 units of packed RBCs were required. The mean length of ICU was 12 days. There were 24 cases of mortality (45.3%); among them, 11 were hemorrhagic (20.8%) ([Table 1](#pone.0236645.t001){ref-type="table"}).

10.1371/journal.pone.0236645.t001

###### Patient characteristics.

![](pone.0236645.t001){#pone.0236645.t001g}

                                           n = 53
  ---------------------------------------- --------------
  Age (years)                              60.7 ± 17.9
  Sex (male)                               32 (60.4%)
  ISS                                      40.2 ± 11.0
  Cardiac arrest in ER                     7 (13.2%)
  DM                                       9/52 (17.3%)
  Anticoagulant use                        7/53 (13.5%)
  Initial SBP (mmHg)                       82.0 ± 34.7
  Initial hemoglobin (g/dL)                10.0 ± 2.8
  Worst lactate level in ER (mmol/L)       6.74 ± 4.13
  Combined injury                          50 (94.3%)
  Pelvic fracture type                     
      APC type II                          2 (3.8%)
      APC type III                         4 (7.5%)
      LC I                                 1 (1.9%)
      LC II                                17 (32.1%)
      LC III                               13 (24.5%)
      VS                                   16 (30.2%)
  Time to PPP from ER arrival (mins)       87 (26--555)
  Pelvic external fixation                 10 (18.9%)
  Emergent pelvic angiography              12 (22.6%)
  Concurrent laparotomy                    13 (24.5%)
  Hemostatic gauze use                     21 (39.6%)
  Packed RBC requirement for 4h (units)    12.0 ± 9.6
  Packed RBC requirement for 12h (units)   5.4 ± 5.1
  Total packed RBC requirement (units)     21.8 ± 11.6
  Time to tape removal (hour)              45.5 ± 21.1
  Duration of hospitalization (day)        29 (1--257)
  Duration of ICU stay (day)               12 (1--255)
  Mortality                                24 (45.3%)
  Mortality due to hemorrhage              11 (20.8%)

ISS: Injury severity score, ER: emergency room, DM: Diabetes mellitus, SBP: Systolic blood pressure, APC: Anterior-posterior compression, LC: Lateral compression, VS: Vertical shear, PPP: Pre-peritoneal pelvic packing, RBC: Red blood cells, ICU: Intensive care unit.

3.2 HG group vs. control group before PSM {#sec015}
-----------------------------------------

The comparison of the 21 patients in the HG group and the 32 patients in the control group revealed no significant difference in age. However, the ratio of patients \>75 years of age was significantly different (38.1% vs. 12.5%, p = 0.045). The mean value of the highest lactate level in each group was not different (5.7 ± 3.7 vs. 7.4 ± 4.3 mmol/L, p = 0.150). The ratio of patients who had lactate levels \> 4 mmol/L in the control group was significantly higher than of patients who had lactate levels \> 4 mmol/L in the HG group (84.4% vs. 57.1%, p = 0.028). The other variables in the groups were not different ([Table 2](#pone.0236645.t002){ref-type="table"}). Comparison of the clinical outcomes revealed no significant intergroup differences ([Table 3](#pone.0236645.t003){ref-type="table"}).

10.1371/journal.pone.0236645.t002

###### Hemostatic gauze group vs. control group before propensity score matching.

![](pone.0236645.t002){#pone.0236645.t002g}

                                                Hemostatic gauze group n = 21   Control group n = 32   p-value
  --------------------------------------------- ------------------------------- ---------------------- --------------------------------------------
  Age (years)                                   65.4 ± 19.5                     57.7 ± 16.4            0.126
      Age \> 75                                 8 (38.1%)                       4 (12.5%)              0.045[\*](#t002fn001){ref-type="table-fn"}
  Sex (male)                                    13 (61.9%)                      19 (59.4%)             0.854
  ISS                                           38.2 ± 9.8                      41.5 ± 11.7            0.296
  Cardiac arrest in ER                          2 (9.5%)                        5 (15.6%)              0.690[\*](#t002fn001){ref-type="table-fn"}
  DM                                            2 (9.5%)                        7 (22.6%)              0.283[\*](#t002fn001){ref-type="table-fn"}
  Anticoagulant use                             4 (19.0%)                       3 (9.7%)               0.420[\*](#t002fn001){ref-type="table-fn"}
  Initial SBP                                   78.9 ± 36.5                     84.1 ± 33.8            0.598
      Initial SBP \< 90 mmHg                    15 (71.4%)                      20 (62.5%)             0.502
  Initial hemoglobin (g/dL)                     10.3 ± 2.7                      9.8 ± 2.9              0.478
  Worst lactate level in ER (mmol/L)            5.7 ± 3.7                       7.4 ± 4.3              0.150
      Worst lactate level in ER \> 4 (mmol/L)   12 (57.1%)                      27 (84.4%)             0.028
  Combined injury                               18 (85.7%)                      32 (100%)              0.057
  Pelvic fracture type                                                                                 0.986[\*](#t002fn001){ref-type="table-fn"}
      APC type II                               1 (4.8%)                        1 (3.1%)               
      APC type III                              1 (4.8%)                        3 (9.4%)               
      LC I                                      0                               1 (3.1%)               
      LC II                                     7 (33.3%)                       10 (31.3%)             
      LC III                                    5 (23.8%)                       8 (25.0%)              
      VS                                        7 (33.3%)                       9 (28.1%)              
  Pelvic external fixation                      4 (19.0%)                       6 (18.8%)              1.000[\*](#t002fn001){ref-type="table-fn"}
  Emergent pelvic angiography                   5 (23.8%)                       7 (21.9%)              0.869

\*Result of Fisher's exact test

ISS: Injury severity score, ER: emergency room, DM: Diabetes mellitus, SBP: Systolic blood pressure, APC: Anterior-posterior compression, LC: Lateral compression, VS: Vertical shear.

10.1371/journal.pone.0236645.t003

###### Comparison of clinical outcomes between the hemostatic gauze group and the control group before propensity scoring matching.

![](pone.0236645.t003){#pone.0236645.t003g}

                                           Hemostatic gauze group n = 21   Control group n = 32   p-value
  ---------------------------------------- ------------------------------- ---------------------- ---------
  Packed RBC requirement for 4h (units)    11.6 ± 6.5                      12.3 ± 11.2            0.785
  Packed RBC requirement for 12h (units)   4.1 ± 3.5                       6.3 ± 5.9              0.094
  Total packed RBC requirement (units)     20.0 ± 9.3                      23.1 ± 12.9            0.346
  Time to tape removal (hours)             52.6 ± 20.1                     41.5 ± 20.9            0.116
  Duration of hospitalization (days)       26 (1--129)                     30 (1--257)            0.084
  Duration of ICU stay (days)              7 (1--40)                       12.5 (1--255)          0.204
  Mortality                                12 (57.1%)                      12 (37.5%)             0.160
  Mortality due to hemorrhage              5 (23.8%)                       6 (18.8%)              0.657

RBC: Red blood cells, ICU: Intensive care unit

\*Result of Fisher's exact test

3.3 HG group vs. control group after PSM {#sec016}
----------------------------------------

One-to-one PSM was performed for three variables that showed statistical differences (age \> 75 years, serum lactate \> 4 mmol/L, and sex). Comparison of the 21 patients from both groups using PSM identified no additional significant differences. In other words, the basic clinical variables for both groups were properly revised ([Table 4](#pone.0236645.t004){ref-type="table"}). When clinical outcome was compared between the HG and the control groups, mortality due to hemorrhage (23.8% vs. 19.1%, p = 1.00) did not differ significantly. However, significantly lower amounts of packed RBCs were required in the HG group for an additional 12 hours than for the control group (4.1 ± 3.5 vs. 7.6 ± 6.1 units, p = 0.035). Although there were no statistically significant intergroup differences in length of hospital and ICU stays, both variables tended to be shorter in the HG group (length of ICU stay, 11.6 vs. 18.5 days, p = 0.158; length of hospital stay, 30.8 vs. 47.4 days, p = 0.186) ([Table 5](#pone.0236645.t005){ref-type="table"}).

10.1371/journal.pone.0236645.t004

###### Hemostatic gauze group vs. control group after PSM.

![](pone.0236645.t004){#pone.0236645.t004g}

                                                          Hemostatic gauze group n = 21   Control group n = 21   p-value
  ------------------------------------------------------- ------------------------------- ---------------------- ---------
  Age (years)                                             65.4 ± 19.5                     59.1 ± 18.1            0.289
      Age \> 75                                           8 (38.1%)                       4 (19.1%)              0.306
  Sex (male)                                              13 (61.9%)                      14 (66.7%)             1.000
  ISS                                                     38.2 ± 9.8                      40.1 ± 9.8             0.532
  Cardiac arrest in ER                                    2 (9.5%)                        2 (9.5%)               1.000\*
  DM                                                      2 (9.5%)                        6 (30.0%)              0.130\*
  Anticoagulant use[‡](#t004fn001){ref-type="table-fn"}   4 (19.0%)                       3 (15.0%)              1.000\*
  Initial SBP                                             78.9 ± 36.5                     97.6 ± 30.3            0.077
      Initial SBP \< 90 mmHg                              15 (71.4%)                      10 (47.6%)             0.208
  Initial hemoglobin (g/dL)                               10.3 ± 2.7                      10.0 ± 2.7             0.750
  Worst lactate level in ER (mmol/L)                      5.7 ± 3.7                       6.4 ± 3.5              0.525
      Worst lactate level in ER \> 4 (mmol/L)             12 (57.1%)                      16 (76.2%)             0.326
  Combined injury                                         18 (85.7%)                      21 (100%)              0.232
  Pelvic fracture type                                                                                           0.676\*
      APC type II                                         1 (4.8%)                        1 (4.8%)               
      APC type III                                        1 (4.8%)                        2 (9.5%)               
      LC I                                                0                               1 (4.8%)               
      LC II                                               7 (33.3%)                       8 (38.1%)              
      LC III                                              5 (23.8%)                       5 (23.8%)              
      VS                                                  7 (33.3%)                       4 (19.1%)              
  Pelvic external fixation                                4(19.0%)                        4(19.0%)               1.000\*
  Emergent pelvic angiography                             5 (23.8%)                       4 (19.0%)              1.000\*

‡data missing = 1, Results of Fisher's exact test

ISS: Injury severity score, ER: emergency room, DM: Diabetes mellitus, SBP: Systolic blood pressure, APC: Anterior-posterior compression, LC: Lateral compression, VS: Vertical shear, PSM: propensity score matching.

10.1371/journal.pone.0236645.t005

###### Comparison of clinical outcomes between hemostatic gauze group and control group after PSM.

![](pone.0236645.t005){#pone.0236645.t005g}

                                           Hemostatic gauze group n = 21   Control group n = 21   p-value
  ---------------------------------------- ------------------------------- ---------------------- ---------
  Packed RBC requirement for 4h (units)    11.6 ± 6.5                      12.1 ± 12.3            0.852
  Packed RBC requirement for 12h (units)   4.1 ± 3.5                       7.6 ± 6.1              0.035
  Total packed RBC requirement (units)     20.0 ± 9.3                      24.3 ± 14.3            0.252
  Time to tape removal (hours)             52.6 ± 20.1                     40.4 ± 22.7            0.127
  Duration of hospitalization (days)       30.8 (1--129)                   47.4 (1--130)          0.186
  Duration of ICU stay (days)              11.6 (1--40)                    18.5 (1--76)           0.158
  Mortality                                12 (57.1%)                      8 (38.1%)              0.354
  Mortality due to hemorrhage              5 (23.8%)                       4 (19.1%)              1.000

RBC: Red blood cells, ICU: Intensive care unit, PSM: propensity score matching.

4 Discussion {#sec017}
============

In this study, the mean injury severity score was 40.2 ± 11.0; 13.2% of patients were in cardiac arrest on arrival at the ER, and the mean lactate level in the ER was 6.74 mmol/L. Therefore, patients enrolled in this study were hemodynamically unstable and may have had severe coagulopathy. Since coagulopathy can be aggravated by hypothermia and metabolic acidosis in patients with hemorrhagic shock, we hypothesized that the difference in the ratio of patients with a lactate level \> 4 mmol/L between the HG group and control group in this study influenced the amount of hemorrhage in both groups. A study on patients with pelvic bone fractures showed that hypothermia and elevated serum lactate levels were predictors of hemorrhage control interventions \[[@pone.0236645.ref015]\]. In addition, in the present study, the number of patients \>75 years old differed significantly between the two groups. Therefore, these three variables (age, sex, and lactate level) were independent variables in PSM to compensate for differences in patient characteristics between the HG group and control group. In the present study, although there was no difference in hemorrhagic mortality rates between the compensated HG group and the control group, the number of transfusions for an additional 12 hours in the HG group was significantly lower than that in the control group.

After the use of kaolin-impregnated gauze was initially reported in the military setting to stop bleeding due to external wounds, hemostatic effects started being reported in civilian cohorts \[[@pone.0236645.ref009], [@pone.0236645.ref016]\], while some animal studies showed effective intracorporeal hemostasis using this type of gauze \[[@pone.0236645.ref011], [@pone.0236645.ref014]\]. Inaba et al. reported that the amount of bleeding during gauze packing was significantly lower in the kaolin-impregnated hemostatic gauze group than in the standard gauze group in a randomized controlled animal trial using a damage-control swine model with grade IV liver injury \[[@pone.0236645.ref017]\]. However, the number of human studies was limited, with very few on intracorporeal use with this gauze type \[[@pone.0236645.ref010], [@pone.0236645.ref018], [@pone.0236645.ref019]\].

Choron et al. showed that the use of kaolin-impregnated hemostatic gauze and laparotomy pads did not differ from standard packing in terms of the amount of intraoperative transfusions and complications that developed by intra-abdominal packing, although the group using kaolin-impregnated hemostatic gauze and laparotomy pads in damage-control laparotomy had more severe physiologic derangement than did the control group \[[@pone.0236645.ref019]\]. Additionally, the incidence of infectious complications such as wound infection, dehiscence, and intra-abdominal abscess was not statistically different between the two groups \[[@pone.0236645.ref013]\].

Uncontrolled hemorrhage remains a major cause of mortality and morbidity in military and civilian trauma \[[@pone.0236645.ref020]\]. In our study, hemorrhagic mortality rates did not differ significantly between the two groups; however, the HG group (5, 23.8%) showed a slightly higher rate than the control group (4, 19.1%) (p = 1.000). The use of QCG alone would limit the reduction of hemorrhagic mortality for the enrolled patients because of the severity of the hemorrhages.

Kaolin-impregnated hemostatic gauze promotes clotting by activating factors XII and XI in the intrinsic coagulation pathway \[[@pone.0236645.ref020]\]. A recent prospective experimental study used kaolin-impregnated hemostatic gauze in a hypothermic swine model. The test group, which was intentionally hemodiluted with large amounts of IV fluid, showed significantly less bleeding than the control group. These results suggest that kaolin-impregnated hemostatic gauze can be used effectively in coagulopathy-induced traumatic hemorrhagic patients \[[@pone.0236645.ref021]\]. This outcome was similar to that in the present study in which the transfusion volume for an additional 12 hours was lower in the HG group than in the control group. In our research, transfusions were performed within 4 hours before and during surgery, with no significant intergroup differences during the first 4 hours. These data, however, did not assist with the evaluation of the hemostatic effect of kaolin-impregnated hemostatic gauze. Conversely, since blood transfusion volumes for an additional 12 hours were determined by coagulopathy and bony and venous bleeding after damage control surgery, the volumes during this period might indirectly reflect the hemostatic effect of packed kaolin-impregnated hemostatic gauze.

This study has some limitations. It was a single-center retrospective study and included a small number of patients. Therefore, PSM was possible using only 3 variables. Despite these limitations, this study is meaningful since it showed that the use of kaolin-impregnated hemostatic gauze as a packing material during PPP in patients with hemodynamic instability due to pelvic fractures reduced the amount of blood loss for an additional 12 hours without an increase in postoperative wound infections. Further randomized control studies on this topic are needed.

5 Conclusions {#sec018}
=============

Hemostatic gauze during PPP can be effectively used to reduce blood loss for patients with hemodynamic instability due to severe pelvic fractures.

We thank the staff members of the regional trauma centers in Korea for their enthusiasm and commitment to patient care.
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:   preperitoneal pelvic packing
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:   propensity score matching
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:   red blood cells

SI

:   sacroiliac
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We will update your Data Availability statement to reflect the information you provide in your cover letter.

5\. Your ethics statement must appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please move it to the Methods section and delete it from any other section. Please also ensure that your ethics statement is included in your manuscript, as the ethics section of your online submission will not be published alongside your manuscript.

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Partly

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The authors studied in a retrospective study a comparison between HG and CG in PPP for hemodynamically unstable pelvic fractures. They utilized propensity matching technique.

The co-primary outcomes were the rate of occurrence of postoperative wound infections and hemorrhage induced mortality (does not exactly reflect the title)

They demonstrated no differences in wound infections between the two groups, although the number of patients was too small to really conclude this (by the way-high rate of infections...). Beside the need for a larger N, since the focus of the study id wound infection, a detail of the organisms involved would be useful.

Cardiac arrest in the ER was included- were these patients successfully resuscitated and taken to the OR?

12 patients received angiography and angioembolization? What was the distribution between the groups?

Is it your institution practice to use either HG or CG at surgeon discretion? Since this is a retrospective study one cannot determine if the choice of treatment was based on severity of patient condition therefore may introduce a treatment bias.

Figure 2, I would recommend to delete.

In general, absent a protocol/guideline on when to use PPP vs angio etc.. it is difficult to conduct a retrospective study and in addition to a very small cohort.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0236645.r002

Author response to Decision Letter 0

17 Apr 2020

Dear. Editor in chief and review.

Thank you for your comments. I trust that this manuscript will be more fruitful by your comments. We really appreciate it. We revised this manuscript point to point. Thank you.

The authors are required to respond to the reviewer\'s comments and to add a brief about their standard of care of patients with pelvic ring injury associated with haemodnamic instability. This will explain the use of HG in the study group and the role of angio-embolization.

\--\> Thank you for your comment. It\'s good opinion. I appreciate it. According to our guideline for pelvic bone fracture with hemodynamically unstable based on the Rocky Mountain Regional Trauma Center at Denver Health, we perform PPP and/or EF and if bleeding is ongoing, perform pelvic angiography, which is 2ndary following PPP. I explained it little bit more in method section. In addition, there is no criteria for the use of hemostatic gauze and it was determined by surgeons. I add it in method section.

Although the authors discussed the small sample size as a limitation of the study, they did not mention the cause of including only 53 out of 75 patients with PPP.

\--\> Yes. Actually, small sample size is a limitation of this study. Among 75 patients, we excluded 22 patients. Because PPP didn\'t undergo for these 22 patients. We explained that in patient selection and data collection section before. I highlighted it sky blue color.

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at <http://www.plosone.org/attachments/PLOSOne_formatting_sample_main_body.pdf> and <http://www.plosone.org/attachments/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

-\> We did it according to your comment. Thanks.

2\. Please provide additional details regarding participant consent. In the ethics statement in the Methods and online submission information, please ensure that you have specified (1) whether consent was suitably informed and (2) what type you obtained (for instance, written or verbal). If your study included minors under age 18, state whether you obtained consent from parents or guardians. If the need for consent was waived by the ethics committee, please include this information.

-\> We did it accordiing to your comment. Thanks.

3\. Thank you for stating the following financial disclosure:

\"The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.\"

At this time, please address the following queries:

a.Please clarify the sources of funding (financial or material support) for your study. List the grants or organizations that supported your study, including funding received from your institution.

b.State what role the funders took in the study. If the funders had no role in your study, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."

c.If any authors received a salary from any of your funders, please state which authors and which funders.

d.If you did not receive any funding for this study, please state: "The authors received no specific funding for this work."

-\> I put this comment \"The authors received no specific funding for this work.\"

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The authors studied in a retrospective study a comparison between HG and CG in PPP for hemodynamically unstable pelvic fractures. They utilized propensity matching technique.

The co-primary outcomes were the rate of occurrence of postoperative wound infections and hemorrhage induced mortality (does not exactly reflect the title)

\--\> We changed the study title to 'Safety and effectiveness of Kaolin-impregnated hemostatic gauze use in preperitoneal pelvic packing for patients with pelvic fractures and hemodynamic instability: propensity score matching analysis'.

They demonstrated no differences in wound infections between the two groups, although the number of patients was too small to really conclude this (by the way-high rate of infections...). Beside the need for a larger N, since the focus of the study id wound infection, a detail of the organisms involved would be useful.

-\> Thanks for comments. Therefore, I add this sentence. \"Identified microorganisms in the HG group were Staphylococcus epidermidis, Staphylococcus epidermidis and Enterobacter aerogenes for one patient, and Enterococcus faecalis. Staphylococcus epidermidis, E.coli, and Methicillin resistent Staphylococcus capitis were identified in the CG.\"

Cardiac arrest in the ER was included- were these patients successfully resuscitated and taken to the OR?

\--\> Yes. We included those who were successfully resuscitated in the ER.

12 patients received angiography and angioembolization? What was the distribution between the groups?

\--\> According to the protocol, secondary pelvic angiography following PPP was performed in cases of ongoing bleeding even if PPP was performed. Embolization procedures were performed in cases of contrast media extravasations during pelvic angiography. Pelvic angiography was performed for 5 patients in the HG group and 4 patients in the CG (table 4). Pelvic angioembolization was performed for 2 patients in the CG, and 1 patient in the HG group (out of table).

Is it your institution practice to use either HG or CG at surgeon discretion? Since this is a retrospective study one cannot determine if the choice of treatment was based on severity of patient condition therefore may introduce a treatment bias.

\--\> Yes. When performing PPP, there were no criteria for the use of hemostatic gauze and it was determined by surgeon. But, it wasn\'t based on severity. The usage of hemostatic gauze was used randomly. We used propensity scoring matching, because there are some differences of characteristics in both groups which is definitely limitation of retrospective study.

Figure 2, I would recommend to delete.

\--\> Thank you for the comment. I will do it.

In general, absent a protocol/guideline on when to use PPP vs angio etc.. it is difficult to conduct a retrospective study and in addition to a very small cohort.

\--\> Thanks for your comment. Actually we have protocol. I mentioned it in material and method section.

The management protocol for pelvic fractures with hemodynamically unstable was initiated in our trauma center in May 2014 according to management protocols created by the Rocky Mountain Regional Trauma Center at Denver Health (12).

According to the protocol, secondary pelvic angiography following PPP was performed in cases of ongoing bleeding even if PPP was performed. Embolization procedures were performed in cases of contrast media extravasations during pelvic angiography. In cases requiring external fixator (EF) application, pelvic binders were not re-applied; rather, these were re-applied just after PPP, but only in cases without EF use. Pelvic binders were removed after patients became hemodynamically stable.

Thank you again. We hope that you can keep safe in the situation.

Sincerely,

Ji Young Jang, M.D.

Department of Surgery, Trauma Center, National Health Insurance Service Ilsan Hospital

100 Ilsan-ro, Ilsan-donggu, Goyang-si, Gyenggi-do, Republic of Korea

Tel: +82-31-900-3624

E-mail: <drjangjiyoung@gmail.com>, <jyjang@hanmail.net>

###### 

Submitted filename: Rebuttal letter.docx

###### 

Click here for additional data file.

10.1371/journal.pone.0236645.r003
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8 Jun 2020

PONE-D-19-34531R1

Safety and effectiveness of kaolin-impregnated hemostatic gauze use in preperitoneal pelvic packing for patients with pelvic fractures and hemodynamic instability: propensity score matching analysis

PLOS ONE

Dear Dr. Jang,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Jul 23 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <plosone@plos.org>. When you\'re ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled \'Manuscript\'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

We look forward to receiving your revised manuscript.

Kind regards,

Osama Farouk

Academic Editor

PLOS ONE

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: (No Response)

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Partly

Reviewer \#2: Partly

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: I Don\'t Know

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: No

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: No

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Although the authors modified the title to reflect the subject of their results, the primary outcome remains wound infections and as such this manuscript does not discuss or present adequate data on infections. For example a table on microorganisms, antibiotics, localized infection vs sepsis etc\...

Again the size of this study is a major limitation.

Reviewer \#2: I would like to thank the authors for their article and the valuable information. I have the following comments and questions.

I think that the major concerns from the readers side about your work would be:

1\. Lines 90 - 101: The primary aim of your study was to evaluate the safety and effectiveness of kaolin-impregnated hemostatic gauze in PPP for patients with hemodynamic instability due to severe pelvic fractures. Between lines 90 - 101, you were describing your protocol for the management of patients with hemodynamic instability and pelvic fractures. You described the use of pelvic binders and external fixation according to the preference of the orthopaedic surgeons in the trauma team. When you analysed the results of kaolin-impregnated hemostatic gauze versus the control group PPP, we can\'t find data about how many patients had external fixation in each arm and how many patients had only pelvic binders. I think this is a very important piece of information to see if there any significant difference in the rates of external fixation vs pelvic binders in each treatment group. Furthermore, we can\'t find any data about the types or technique of external fixator, if it was C-clamp, supra-acetabular anterior external fixation, etc.

2\. Lines 150 - 161: Regarding the patients\' characteristics in your study, there were 17 patients LC-II (32%) and one patient LC-I. Hemodynamic instability with pelvic fractures are known to be significantly prevalent in pelvic fractures APC-III, LC-III and VS according to the data published by Young and Burgess in 1990 and according to our personal experience. However in your patient group, you have more patients with LC-II injuries compared to VS (30%) and APC-III (7.5%). Can you please explain this?

Other comments:

3\. Line 71: Your study is a retrospective analysis or prospectively collected data and according to the patients and methods (Because the data were analyzed anonymously, informed consent was exempted.), however in line 71, you state in your inclusion criteria (3. agree to the collection and use of their medical information.). If the informed consent was exempted.

4\. Lines 195 -198: I think details of identified micro-organisms in both treatment groups can be removed. Most important was the rates of deep infection.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: Yes: Mohamed Kenawey

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0236645.r004

Author response to Decision Letter 1

30 Jun 2020

Dear. Editor in chief and reviewers.

Thank you for your comments. I trust that this manuscript will be more fruitful by your comments. We really appreciate it. We revised this manuscript point to point. Thank you.

Reviewer \#1: Although the authors modified the title to reflect the subject of their results, the primary outcome remains wound infections and as such this manuscript does not discuss or present adequate data on infections. For example a table on microorganisms, antibiotics, localized infection vs sepsis etc\...

Again the size of this study is a major limitation.

\--\> We agree with the reviewer's opinion and exclude wound infection from the primary outcome. Accordingly, the contents related to wound infection were removed from the manuscript and 'safety' was also excluded from the title of the study.

In addition, I fully agree with the reviewer's comments on the small study population. However, in this study, propensity score matching was performed to compensate for the problems of the small sized retrospective study, and the normality test of the two groups was checked to confirm the normal distribution of the two groups to confirm the statistical adequacy. So, we think our paper is unique, as there are no previous studies on the use of hemostatic gauze in patients with PPP. The results of this study are also meaningful in that they present on hypothesis for future randomized controlled studies. Through this, I think we can expect that a better hemostatic effect in patients undergoing PPP.

Thank you very much for your important review.

Reviewer \#2: I would like to thank the authors for their article and the valuable information. I have the following comments and questions.

I think that the major concerns from the readers side about your work would be:

1\. Lines 90 - 101: The primary aim of your study was to evaluate the safety and effectiveness of kaolin-impregnated hemostatic gauze in PPP for patients with hemodynamic instability due to severe pelvic fractures. Between lines 90 - 101, you were describing your protocol for the management of patients with hemodynamic instability and pelvic fractures. You described the use of pelvic binders and external fixation according to the preference of the orthopaedic surgeons in the trauma team. When you analysed the results of kaolin-impregnated hemostatic gauze versus the control group PPP, we can\'t find data about how many patients had external fixation in each arm and how many patients had only pelvic binders. I think this is a very important piece of information to see if there any significant difference in the rates of external fixation vs pelvic binders in each treatment group. Furthermore, we can\'t find any data about the types or technique of external fixator, if it was C-clamp, supra-acetabular anterior external fixation, etc.

�

\--\> Although orthopedic surgeons in our hospital decided whether or not to perform external fixation, it was performed in only 18.9% of unstable patients due to the lack of trauma-dedicated orthopedic surgeon in Korea. Thus, our protocol includes the application of the pelvic binder in the emergency room in all pelvic fracture patients with shock. External fixation application rates in both groups were added to the manuscript (Table 1,2,4). All external fixation was supra-acetabular external fixation and C-Clamp was not used in our trauma center. We added this contents to the material and method section.

2\. Lines 150 - 161: Regarding the patients\' characteristics in your study, there were 17 patients LC-II (32%) and one patient LC-I. Hemodynamic instability with pelvic fractures are known to be significantly prevalent in pelvic fractures APC-III, LC-III and VS according to the data published by Young and Burgess in 1990 and according to our personal experience. However in your patient group, you have more patients with LC-II injuries compared to VS (30%) and APC-III (7.5%). Can you please explain this?

\--\> Authors agree with the reviewer's opinion. There are several reasons for the high proportion of LCII in our cohort and relatively low proportion of APCII and APCIII.

First, because the trauma system in our area has not fully organized, 68% (36/53) of patients have been transferred from other hospitals to our trauma center, and the mean time from accident to ER arrival was 156 minutes, which is quite long. We think that Hemodynamically unstable patients with more severe pelvic fracture such as APC III or VS died prior to hospital arrival.

Second, in our cohort, the pedestrian TA was 41.5% and the average age of patients was 60, which is relatively high compared to other cohorts. For these reasons, pelvic fracture caused by low energy injury often cause shock. These also seems to be the reason for the high proportion of LCII pelvic fracture patients in our cohort.

Other comments:

3\. Line 71: Your study is a retrospective analysis or prospectively collected data and according to the patients and methods (Because the data were analyzed anonymously, informed consent was exempted.), however in line 71, you state in your inclusion criteria (3. agree to the collection and use of their medical information.). If the informed consent was exempted.

\--\> Third inclusion criterion was wrong, so we deleted it.

4\. Lines 195 -198: I think details of identified micro-organisms in both treatment groups can be removed. Most important was the rates of deep infection.

\--\> Yes, I agree with the reviewer's comments and have deleted this.

Thank you for your thoughtful review.

###### 

Submitted filename: Author response.docx

###### 

Click here for additional data file.

10.1371/journal.pone.0236645.r005
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13 Jul 2020

Effectiveness of kaolin-impregnated hemostatic gauze use in preperitoneal pelvic packing for patients with pelvic fractures and hemodynamic instability: propensity score matching analysis

PONE-D-19-34531R2

Dear Dr. Jang,

We're pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you'll receive an e-mail detailing the required amendments. When these have been addressed, you'll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at <http://www.editorialmanager.com/pone/>, click the \'Update My Information\' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible \-- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

Kind regards,

Osama Farouk

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: (No Response)

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: (No Response)

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: (No Response)

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: (No Response)

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: (No Response)

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

10.1371/journal.pone.0236645.r006
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15 Jul 2020

PONE-D-19-34531R2

Effectiveness of kaolin-impregnated hemostatic gauze use in preperitoneal pelvic packing for patients with pelvic fractures and hemodynamic instability: a propensity score matching analysis

Dear Dr. Jang:

I\'m pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they\'ll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

If we can help with anything else, please email us at <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Osama Farouk

Academic Editor

PLOS ONE

[^1]: **Competing Interests:**The authors have declared that no competing interests exist.
